MA53322A - Anticorps procoagulants améliorés - Google Patents

Anticorps procoagulants améliorés

Info

Publication number
MA53322A
MA53322A MA053322A MA53322A MA53322A MA 53322 A MA53322 A MA 53322A MA 053322 A MA053322 A MA 053322A MA 53322 A MA53322 A MA 53322A MA 53322 A MA53322 A MA 53322A
Authority
MA
Morocco
Prior art keywords
procoagulant antibodies
enhanced procoagulant
enhanced
antibodies
procoagulant
Prior art date
Application number
MA053322A
Other languages
English (en)
Inventor
Jianhe Chen
Per J Greisen
Bjarne Gram Hansen
Mikkel Nors Harndahl
Eva Johansson
Laust Bruun Johnsen
Morten Grønbech Rasch
Anders Svensson
Karina Thorn
Zhiru Yang
Rong Zhou
Haisun Zhu
Henrik Østergaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA53322A publication Critical patent/MA53322A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053322A 2018-08-01 2019-07-31 Anticorps procoagulants améliorés MA53322A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018097834 2018-08-01
CN2018099339 2018-08-08
EP18193191 2018-09-07

Publications (1)

Publication Number Publication Date
MA53322A true MA53322A (fr) 2021-11-10

Family

ID=67480228

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053322A MA53322A (fr) 2018-08-01 2019-07-31 Anticorps procoagulants améliorés

Country Status (18)

Country Link
US (1) US20230058721A1 (fr)
EP (1) EP3830135A1 (fr)
JP (3) JP6761142B1 (fr)
KR (2) KR20210091839A (fr)
CN (3) CN117384296A (fr)
AU (1) AU2019313550B2 (fr)
BR (1) BR112021000823A2 (fr)
CA (1) CA3113797A1 (fr)
CL (1) CL2021000186A1 (fr)
CO (1) CO2021001046A2 (fr)
IL (1) IL280239A (fr)
MA (1) MA53322A (fr)
MX (1) MX2021001064A (fr)
PE (1) PE20211399A1 (fr)
PH (1) PH12021550117A1 (fr)
SG (1) SG11202100418PA (fr)
TW (1) TWI716059B (fr)
WO (1) WO2020025672A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021152066A1 (fr) * 2020-01-30 2021-08-05 Novo Nordisk A/S Anticorps mimétiques bispécifiques du facteur viii
KR20230130558A (ko) 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체의 월 1회 투여 방법
KR20230130561A (ko) 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법
KR20230130560A (ko) 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체의 주 1회 투여 방법
WO2024008904A2 (fr) 2022-07-08 2024-01-11 Novo Nordisk A/S Composés isvd hautement puissants capables de remplacer fviii(a)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
ES2246069T3 (es) * 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
US20080075712A1 (en) * 2003-10-14 2008-03-27 Kunihiro Hattori Double Specific Antibodies Substituting For Functional Proteins
EP2824183B1 (fr) * 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production d'anticorps bispécifiques
US9334331B2 (en) 2010-11-17 2016-05-10 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies
HUE040580T2 (hu) * 2012-05-10 2019-03-28 Bayer Pharma AG XI. véralvadási faktorhoz és/vagy XIA aktivált alakjához kötõdni képes ellenanyagok és alkalmazásuk
TW201605904A (zh) * 2013-11-07 2016-02-16 諾佛 儂迪克股份有限公司 治療凝血病變之新穎方法及抗體
TWI700300B (zh) * 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
CA2978038A1 (fr) * 2015-04-17 2016-10-20 F. Hoffmann-La Roche Ag Polytherapie avec des facteurs de coagulation et des anticorps polyspecifiques
CN110662770A (zh) * 2016-11-23 2020-01-07 比奥维拉迪维治疗股份有限公司 结合凝血因子ix和凝血因子x的双特异性抗体
EP3577140A1 (fr) 2017-02-01 2019-12-11 Novo Nordisk A/S Anticorps procoagulants
US11220554B2 (en) * 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies

Also Published As

Publication number Publication date
JP7355874B2 (ja) 2023-10-03
TW202007696A (zh) 2020-02-16
CN112513096A (zh) 2021-03-16
CA3113797A1 (fr) 2020-02-06
IL280239A (en) 2021-03-25
JP2020115863A (ja) 2020-08-06
KR102382743B1 (ko) 2022-04-12
WO2020025672A1 (fr) 2020-02-06
CN112513096B (zh) 2023-08-25
PE20211399A1 (es) 2021-07-27
JP2020530449A (ja) 2020-10-22
CL2021000186A1 (es) 2021-07-02
KR20210040389A (ko) 2021-04-13
TWI716059B (zh) 2021-01-11
CN117343188A (zh) 2024-01-05
JP6761142B1 (ja) 2020-09-23
CO2021001046A2 (es) 2021-04-30
JP7094314B2 (ja) 2022-07-01
EP3830135A1 (fr) 2021-06-09
AU2019313550A1 (en) 2021-02-04
JP2022084858A (ja) 2022-06-07
SG11202100418PA (en) 2021-02-25
US20230058721A1 (en) 2023-02-23
KR20210091839A (ko) 2021-07-22
CN117384296A (zh) 2024-01-12
MX2021001064A (es) 2021-04-12
PH12021550117A1 (en) 2021-10-04
WO2020025672A9 (fr) 2020-04-23
BR112021000823A2 (pt) 2021-04-13
AU2019313550B2 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
MA53434A (fr) Anticorps anti-tigit
MA47694A (fr) Anticorps anti-tigit
MA52884A (fr) Anticorps anti-il-11
MA49034A (fr) Anticorps anti-lag3
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA47268A (fr) Anticorps anti-gpc3
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA51734A (fr) Anticorps se liant à gprc5d
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA46057A (fr) Anticorps anti-ctla4
MA44381A (fr) Format d'anticorps hétérodimères multispécifiques
MA46041A (fr) Anticorps anti-tim -3
MA44780A (fr) Préparation contenant un anticorps
MA53322A (fr) Anticorps procoagulants améliorés
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA52366A (fr) Anticorps anti-tl1a optimisés
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA49749A (fr) Anticorps anti-cd137
MA52152A (fr) Anticorps
MA51134A (fr) Anticorps anti-alpha-synucléine
MA42843A (fr) Anticorps anti-cd115
MA44236A (fr) Anticorps anti-tgfbêta 2
MA49250A (fr) Nouveaux anticorps anti-cd3
MA44777A (fr) Anticorps humanisés anti-basigine et leur utilisation